Search

Innoviva Inc

Suletud

SektorTervishoid

20.88 -0.38

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.81

Max

21.23

Põhinäitajad

By Trading Economics

Sissetulek

-270M

-83M

Müük

22M

120M

P/E

Sektori keskmine

4.891

57.366

Aktsiakasum

0.59

Kasumimarginaal

-69.754

Töötajad

159

EBITDA

28M

267M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+94.04% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-14M

1.5B

Eelmine avamishind

21.26

Eelmine sulgemishind

20.88

Uudiste sentiment

By Acuity

100%

0%

326 / 340 Pingereas Healthcare

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2026, 20:07 UTC

Innoviva Inc shares are lower today despite a drop in initial jobless claims, indicating resilience in the labor market. The stock reached a session low earlier.

26. aug 2026, 21:01 UTC

Innoviva Inc shares moved lower in after-market trading, retracing from an initial uptick to reach their lowest point by 16:50 ET.

25. aug 2026, 21:02 UTC

Innoviva Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

21. aug 2026, 19:46 UTC

Innoviva Inc's shares are higher during Friday's session, reflecting a modest increase since Thursday's close. No specific news was identified for the movement.

20. aug 2026, 20:02 UTC

Shares of Innoviva Inc are declining amid broader market pressures following Walmart Inc's disappointing earnings report, raising concerns about consumer spending.

19. aug 2026, 19:26 UTC

Innoviva Inc's shares are higher during Wednesday's session, maintaining strength above the 20-day moving average and near the upper end of its one-month range.

18. aug 2026, 20:06 UTC

Innoviva Inc is trading higher, supported by strength in the Pharmaceuticals sub-sector. The stock has shown a steady rise since Monday's close.

14. aug 2026, 19:56 UTC

Innoviva Inc shares are higher during Friday's session, recovering from earlier losses despite no specific news. Broader market sentiment is affected by declining U.S. retail sales.

13. aug 2026, 19:41 UTC

Innoviva Inc shares are lower during Thursday's session, with no specific news identified. The stock remains below its 20-day moving average.

12. aug 2026, 19:06 UTC

Event

Innoviva Inc's therapies are finalists for the 2026 Prix Galien USA Award, but shares are trading lower, remaining below Tuesday's close.

11. aug 2026, 19:16 UTC

Innoviva Inc's shares are higher in Tuesday's session, reflecting a modest gain since Monday's close. The stock remains below its 20-day moving average.

10. aug 2026, 19:16 UTC

News

Innoviva shares are higher despite mixed analyst ratings and a price target cut from Cantor Fitzgerald to $34.00. HC Wainwright maintains a $46.00 target.

7. aug 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6. aug 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5. aug 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3. aug 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31. juuli 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30. juuli 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29. juuli 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28. juuli 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27. juuli 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21. juuli 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20. juuli 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

94.04% tõus

12 kuu keskmine prognoos

Keskmine 40.67 USD  94.04%

Kõrge 46 USD

Madal 34 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

326 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat